See more : The Ogaki Kyoritsu Bank, Ltd. (8361.T) Income Statement Analysis – Financial Results
Complete financial analysis of Entrada Therapeutics, Inc. (TRDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entrada Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Eris Lifesciences Limited (ERIS.BO) Income Statement Analysis – Financial Results
- JER Investors Trust Inc. (JERT) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNY) Income Statement Analysis – Financial Results
- Neurones S.A. (NRO.PA) Income Statement Analysis – Financial Results
- Spin Master Corp. (SNMSF) Income Statement Analysis – Financial Results
Entrada Therapeutics, Inc. (TRDA)
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 129.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 99.88M | 1.90M | 1.12M | 326.00K | 104.00K |
| Gross Profit | 29.13M | -1.90M | -1.12M | -326.00K | -104.00K |
| Gross Profit Ratio | 22.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 99.88M | 66.61M | 35.93M | 21.10M | 8.22M |
| General & Administrative | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Selling & Marketing | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.29M | 30.64M | 15.20M | 5.57M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 6.27M |
| Operating Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Cost & Expenses | 132.18M | 97.25M | 51.13M | 26.67M | 11.82M |
| Interest Income | 15.22M | 2.63M | 0.00 | 144.00K | 451.00K |
| Interest Expense | 0.00 | 2.63M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.84M | 1.90M | 1.12M | 326.00K | 104.00K |
| EBITDA | -321.00K | -95.35M | -50.01M | -26.34M | -11.72M |
| EBITDA Ratio | -0.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.16M | -97.25M | -51.13M | -26.67M | -11.82M |
| Operating Income Ratio | -2.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.22M | 2.63M | -31.00K | 144.00K | 6.72M |
| Income Before Tax | 12.06M | -94.62M | -51.16M | -26.52M | -5.10M |
| Income Before Tax Ratio | 9.34% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.74M | -7.16M | -1.09M | -144.00K | -451.00K |
| Net Income | -6.69M | -87.46M | -50.07M | -26.38M | -4.65M |
| Net Income Ratio | -5.18% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| EPS Diluted | -0.20 | -2.79 | -1.60 | -0.84 | -0.15 |
| Weighted Avg Shares Out | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
| Weighted Avg Shares Out (Dil) | 33.05M | 31.29M | 31.22M | 31.25M | 31.25M |
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of...
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.74 per share a year ago.
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –
Entrada Therapeutics: Early Stage But Interesting
Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly $600mn and received a major deal with Vertex. Preclinical tests have shown high...
New Strong Buy Stocks for July 21st
TRDA, LPRO, TBBK, BMTX and MOTS have been added to the Zacks Rank #1 (Strong Buy) List on July 21, 2023.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
Entrada Therapeutics shares jump on collaboration with Vertex
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that...
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
BOSTON--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada's...
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for...
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nathan...
Source: https://incomestatements.info
Category: Stock Reports